Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
Hamilton EP, Falchook GS, Wang JS, Fu S, Oza AM, Imedio ER, Kumar S, Ottesen L, Mugundu GM, de Bruin EC, O'Connor MJ, Jones SF, Spigel DR, Li BT. Hamilton EP, et al. Among authors: mugundu gm. Target Oncol. 2024 Nov;19(6):879-892. doi: 10.1007/s11523-024-01102-8. Epub 2024 Nov 1. Target Oncol. 2024. PMID: 39487373 Free PMC article. Clinical Trial.
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
Johnson M, Serra Traynor C, Vishwanathan K, Overend P, Hartmaier R, Markovets A, Chmielecki J, Mugundu GM, Barrett JC, Tomkinson H, Ramalingam SS. Johnson M, et al. Among authors: mugundu gm. Clin Pharmacol Ther. 2024 Feb;115(2):349-360. doi: 10.1002/cpt.3113. Epub 2023 Dec 21. Clin Pharmacol Ther. 2024. PMID: 38010260 Clinical Trial.
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Någård M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, Edenfield WJ, Lewis LD, Ottesen LH, Li Y, Mugundu GM. Någård M, et al. Among authors: mugundu gm. Cancer Chemother Pharmacol. 2023 Sep;92(3):193-203. doi: 10.1007/s00280-023-04554-3. Epub 2023 Jul 2. Cancer Chemother Pharmacol. 2023. PMID: 37394627 Free PMC article. Clinical Trial.
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Någård M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, Edenfield WJ, Lewis LD, Rekić D, Dota C, Ottesen LH, Li Y, Mugundu GM. Någård M, et al. Among authors: mugundu gm. Cancer Chemother Pharmacol. 2023 Aug;92(2):141-150. doi: 10.1007/s00280-023-04555-2. Epub 2023 Jun 27. Cancer Chemother Pharmacol. 2023. PMID: 37368100 Free PMC article.
20 results